Medicare Enrolled
Dr. Ronald Scott, M.D.
Interventional Cardiology · Longview, TX
Practice pattern: Cardiac & Electrophysiology— Practice combining cardiac and electrophysiology services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Scott from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Scott? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Scott
Dr. Ronald Scott is an interventional cardiology in Longview, TX, with 19 years in practice. Based on federal Medicare data, Dr. Scott performed 5,884 Medicare services across 3,844 unique beneficiaries.
Between the years covered by Open Payments, Dr. Scott received a total of $12,448 from 40 pharmaceutical and/or device companies across 717 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in interventional cardiology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Scott is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 9% volume in TX$ $12,448 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,884
Medicare services
Top 9% in TX for interventional cardiology
3,844
Unique beneficiaries
$58
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~310 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 752 | $85 | $287 |
| Regadenoson injection (Lexiscan) for heart stress test | 656 | $44 | $152 |
| Electrocardiogram (EKG), 12-lead | 482 | $10 | $45 |
| Remote pacemaker monitoring, 90 days | 481 | $22 | $92 |
| EKG interpretation and report | 413 | $6 | $23 |
| Echocardiogram, transthoracic | 325 | $139 | $599 |
| Prothrombin time test (blood clotting) | 257 | $4 | $15 |
| Anticoagulant management of patient taking warfarin | 244 | $8 | $34 |
| Heart muscle strain imaging | 240 | $28 | $107 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 216 | $19 | $72 |
| Programming of dual lead pacemaker system | 199 | $56 | $156 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 178 | $48 | $203 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 178 | $98 | $1,718 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 174 | $328 | $1,273 |
| Office visit, established patient (20-29 min) | 119 | $65 | $195 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 110 | $10 | $134 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 91 | $26 | $184 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 88 | $19 | $73 |
| Cardiac catheterization | 78 | $186 | $819 |
| Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 73 | $10 | $13 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 45 | $9 | $40 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 45 | $18 | $67 |
| New patient office visit (45-59 min) | 40 | $117 | $439 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 39 | $10 | $40 |
| Hospital follow-up visit, low complexity | 39 | $39 | $106 |
| Initial hospital admission, moderate complexity | 37 | $102 | $371 |
| Hospital follow-up visit, moderate complexity | 35 | $62 | $196 |
| Programming of single lead pacemaker system | 28 | $46 | $134 |
| Coronary stent placement | 27 | $424 | $1,628 |
| New patient office visit (30-44 min) | 27 | $84 | $288 |
| Programming of multiple lead implantable defibrillator system | 26 | $74 | $243 |
| Ultrasound of heart, follow-up | 26 | $62 | $317 |
| Office visit, established patient, complex (40-54 min) | 25 | $120 | $387 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 18 | $200 | $311 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 18 | $190 | $928 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $19 | $73 |
| Heart rhythm recording of continous external ekg over 8-15 days | 16 | $9 | $40 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $397 | $1,425 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 11 | $258 | $1,039 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
21.8% high complexity
22.3% medium
55.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,448
Total received (2018-2024)
Avg $1,778/year across 7 years
Top 38% in TX for interventional cardiology
40
Companies
717
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,434 (99.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$14 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,399
2023$1,959
2022$1,691
2021$2,360
2020$450
2019$1,415
2018$2,174
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Medtronic Vascular, Inc.
$1,306
Novartis Pharmaceuticals Corporation
$1,290
Biosense Webster, Inc.
$1,174
Edwards Lifesciences Corporation
$1,054
Bard Peripheral Vascular, Inc.
$904
Janssen Pharmaceuticals, Inc
$682
Abbott Laboratories
$648
Merck Sharp & Dohme LLC
$511
E.R. Squibb & Sons, L.L.C.
$489
Medtronic, Inc.
$486
Boston Scientific Corporation
$434
Boehringer Ingelheim Pharmaceuticals, Inc.
$398
ShockWave Medical, Inc
$389
Gilead Sciences, Inc.
$308
Amgen Inc.
$305
Inari Medical, Inc.
$274
Cardiovascular Systems Inc.
$212
iRhythm Technologies, Inc.
$197
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$165
Alnylam Pharmaceuticals Inc.
$148
PFIZER INC.
$143
Philips Electronics North America Corporation
$121
SANOFI-AVENTIS U.S. LLC
$110
Kerecis Limited
$90
Shockwave Medical, Inc
$85
ABIOMED
$77
W. L. Gore & Associates, Inc.
$75
Novo Nordisk Inc
$54
Regeneron Healthcare Solutions, Inc.
$49
Actelion Pharmaceuticals US, Inc.
$35
Terumo Medical Corporation
$34
Teleflex LLC
$30
BOSTON SCIENTIFIC CORPORATION
$30
Chiesi USA, Inc.
$30
Amarin Pharma Inc.
$29
Lundbeck LLC
$20
BIOTRONIK INC.
$18
Acist Medical Systems, Inc.
$14
Lexicon Pharmaceuticals, Inc.
$14
AstraZeneca Pharmaceuticals LP
$14
Top 3 companies account for 30.3% of total payments
Associated products mentioned in payments ›
ASSURITY · AURORA EV-ICD MRI SURESCAN · AVEIR · AZURE XT DR MRI SURESCAN · Amplia MRI · Asahi Fielder XT cornary guide wire · Asahi Fielder coronary guide wire · Asahi Sion guide wire · Assurity Pacemaker · Azure · Baylis Medical Company Radiofrequency Puncture Generator · CAMZYOS · CARDIOMEMS · CARTO 3 · CHANTIX · COBALT DR MRI SURESCAN · CRT-Ds · Carto 3 · Carto 3 System · CartoSound · Catheter - Specialty Access · Catheter - Turnpike · Cobalt · Confidense · Confirm Rx · CoreValve Evolut · Corlanor · Diamondback Coronary · Diamondback Peripheral · Durata Defibrillation ICD Lead · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · ELIQUIS · ENTRESTO · EXCLUDER Conformable AAA Endoprosthesis with Active Control · Edwards SAPIEN 3 Transcatheter Heart Valve · Edwards SAPIEN 3 Ultra Transcatheter Heart Valve · Ellipse ICD · FARXIGA · FLOWTRIEVER CATHETER · Fortify Assura · GORE DRYSEAL FLEX Introducer Sheath · GORE EXCLUDER Iliac Branch Endoprosthesis · General - Therapies · Glidesheath · Hi-Torque Pilot guide wire · IGT D Peripheral · IGT_D FM · Impella · Inpefa · JARDIANCE · KENGREAL · Kerecis Omega3 Wound · LEQVIO · LINQ II · LUTONIX · LifeVest · Lutonix Drug Coated Balloon · MICRA · MULTAQ · Merlin Connectivity and Remote · Micra · Mini Trek catheters · Multi-Link Mini Vision coronary stent system · MyCareLink Smart · NC TREK coronary catheters · NORTHERA · ONPATTRO · OPSUMIT · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Peripheral Orbital Atherectomy System · Quadra Allure MP RF CRT Pacemkr · ROTABLATOR · RXi Systems · Repatha · Resolute · Reveal LINQ · S · SAPIEN 3 Ultra RESILIA · SHOCKWAVE IVL SYSTEM WITH THE SHOCKWAVE C2 CORONARY IVL CATHETER · Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter · Soundstar · Spectranetics Undiv · TR BAND · TYRX · Telescope · ULTRASCORE · VERQUVO · Vascepa · VersaCross Access Solution · WATCHMAN · WATCHMAN Access System · WATCHMAN FLX · WOLVERINE · XARELTO · Xience Alpine cornary stent system · Xience Sierra Coronary Stent System · ZIO XT Patch · Zio monitor
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $212 per 100 Medicare services performed
Geographic Context
Interventional Cardiologys within 10 mi
8
Per 100K population
6.4
County median income
$64,809
Nearest hospital
LONGVIEW REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Scott is a cardiac & electrophysiology specialist, with above-average Medicare volume (top 9% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Scott experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Scott performed 752 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Scott receive payments from pharmaceutical companies?
Yes. Dr. Scott received a total of $12,448 from 40 companies across 717 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Scott's costs compare to other interventional cardiologys in Longview?
Dr. Scott's average Medicare payment per service is $58. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Scott) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Interventional Cardiologys in Longview
Browse interventional cardiologys in Longview ranked by procedure volume and transparency data.
Highest volume
Top Interventional Cardiologys in TX
Interventional Cardiologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Interventional Cardiologys in TX
Which TX interventional cardiologys receive the most from drug and device companies.
By company
Medtronic Vascular, Inc. Payments to Doctors
See all physicians who received payments from Medtronic Vascular, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Biosense Webster, Inc. Payments to Doctors
See all physicians who received payments from Biosense Webster, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology